Search

Background and objective Anaplastic lymphoma kinase (ALK) is an important therapeutic target for advanced non-small cell lung cancer (NSCLC). In recent years, with the emergence of several ALK tyrosine kinase inhibitors (TKI), the overall survival (OS) of ALK fusion positive patients is gradually extended. This paper reports the treatment of a late stage non-small cell lung cancer (NSCLC) patient with ALK fusion positive for more than 5 years, and analyzes the treatment process and effect evaluation, so as to provide experience for the follow-up treatment of patients. Methods The diagnosis and treatment process of a patient with advanced ALK fusion mutation positive lung cancer admitted to the third ward of Department of oncology, Chifeng hospital, Inner Mongolia on July 3, 2015 was retrospectively analyzed. Results A 42 years old male patient was admitted to our department on July 3, 2015 for "intermittent cough, chest tightness for 2 months, diagnosed with lung adenocarcinoma for 1 day". Imaging examination showed a space occupying lesion in the left lower lobe of the lung, accompanied by mediastinal lymphadenopathy and left encapsulated pleural effusion. Bronchoscopic pathology showed non-small cell carcinoma, and adenocarcinoma was tentatively suggested. Diagnosis: left lower lobe adenocarcinoma T1bN2M1a stage IV. Fluorescence in situ hybridization (FISH) indicated the translocation of ALK (2p23) chromosome. After 2 cycles of docetaxel+cisplatin (DP) regimens chemotherapy, disease progression occurred, so we used 6 cycles of pemetrexed+carboplatin to apply combination chemotherapy, 4 cycles of pemetrexed monotherapy were used after that. The efficacy evaluation: PR. On April 9, 2016, the patient was treated with crizotinib. In August 2019, multiple intracranial metastases were found and whole brain radiotherapy was given. Since September 4, 2019, oral administration of nsatinib has been carried out. As of March 1, 2021, the patients were followed up well. Conclusion The advanced ALK fusion positive lung adenocarcinoma patients, though the first-line and the second-line chemotherapy, and the follwing application of ALK-TKI treatment, has procured a total OS has reached 68 months, and the current follow-up is good.

Compared with the traditional subtractive and equal manufacturing (SM/EM) computer numerical control (CNC) machining, press working, and casting, additive manufacturing (AM) technology has great advantages in the construction of high-complexity parts. Moreover, its material usage rate is high and the production cycle is short. Therefore, AM is the focus of civil aviation and defense industries, which need high-hardness metal materials and precision machining. However, the thermal history of the AM process affects the geometry of the weld pool, causing the workpiece to fail to meet tolerance requirements. Additionally, large temperature gradients and cooling rate inhomogeneity can also lead to excessive residual stress in the formed parts, which may cause deformation or even fracture of the parts. Factors such as poor dimensional and geometric precision, lower surface quality than that in conventionally formed parts, and poor uniformity of material properties hinder further application of AM. To solve the above problems, the concept of additive and subtractive hybrid manufacturing (ASHM) was developed. Additive and subtractive hybrid manufacturing combines AM with traditional machining and material reduction technology on a single work platform. It involves alternating additive and material reduction operations to improve the surface quality and the geometric and dimensional accuracy of the parts and alleviate residual stress in the parts. According to the different characteristics of an energy source for AM, this paper expounded the technical principle and research progress of ASHM based on arc, laser, and other energy sources and introduced the research progress of the ASHM process. The advantages and disadvantages of the application of this technology in the industrial field were analyzed, and the future development direction of the technology was presented. The ASHM process is expected to become more intelligent, integrated, and standardized in the future.